TITLE:
Papilloma Virus Vaccine Therapy in Treating Young Patients With Recurrent Papilloma of the Larynx

CONDITION:
Precancerous Condition

INTERVENTION:
autologous tumor cell vaccine

SUMMARY:

      RATIONALE: Vaccines made from papilloma virus cells may make the body build an immune
      response to and kill papilloma cells.

      PURPOSE: Phase II trial to study the effectiveness of papilloma virus vaccine in treating
      young patients with recurrent papilloma of the larynx.
    

DETAILED DESCRIPTION:

      OBJECTIVES: I. Determine the immune response in patients with juvenile papilloma of the
      larynx treated with autogenous vaccine derived from each patient's own tumor.

      OUTLINE: Patients receive autogenous papilloma vaccine intradermally and subcutaneously
      weekly for 20 weeks.

      PROJECTED ACCRUAL: Not specified
    

ELIGIBILITY:
Gender: All
Age: 1 Year to N/A
Criteria:

        DISEASE CHARACTERISTICS: Diagnosis of severe recurrent juvenile papilloma of the larynx
        requiring surgery at least 4 times per year Condition must have existed for more than 1
        year

        PATIENT CHARACTERISTICS: Age: 1 and over Performance status: Not specified Life
        expectancy: Not specified Hematopoietic: Not specified Hepatic: Not specified Renal: Not
        specified

        PRIOR CONCURRENT THERAPY: See Disease Characteristics
      
